Immunotherapy for Peritoneal Carcinomatosis (IPC) - A Phase I Study of the Safety and Efficacy of Anti-CEA CAR-T Cell Intraperitoneal Infusions for Treatment of CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Anti CEA CAR T cell therapy Sorrento Therapeutics (Primary)
- Indications Adenocarcinoma; Liver metastases; Malignant ascites; Peritoneal cancer
- Focus Adverse reactions
- Acronyms IPC
- Sponsors Sorrento Therapeutics
- 07 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 07 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.